Indexado en

Enlace externo

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Marti Domenech, M JosepAutor o CoautorBotí González, María De Los ángelesAutor o Coautor

Compartir

Predictors of clinically significant quality of life impairment in Parkinson's disease

Publicado en:Npj Parkinsons Dis. 7 (1): 118-118 - 2021-01-01 7(1), DOI: 10.1038/s41531-021-00256-w

Autores: Santos García D; de Deus Fonticoba T; Cores C; Muñoz G; Paz González JM; Martínez Miró C; Suárez E; Jesús S; Aguilar M; Pastor P; Planellas L; Cosgaya M; García Caldentey J; Caballol N; Legarda I; Hernández Vara J; Cabo I; López Manzanares L; González Aramburu I; Ávila Rivera MA; Catalán MJ; Nogueira V; Puente V; Ruíz de Arcos M; Borrué C; Solano Vila B; Álvarez Sauco M; Vela L; Escalante S; Cubo E; Carrillo Padilla F; Martínez Castrillo JC; Sánchez Alonso P; Alonso Losada MG; López Ariztegui N; Gastón I; Clavero P; Kulisevsky J; Blázquez Estrada M; Seijo M; Rúiz Martínez J; Valero C; Kurtis M; de Fábregues O; González Ardura J; Ordás C; López Díaz LM; McAfee D; Martinez-Martin P; Mir P; COPPADIS Study Group COPPADIS Study Group

Afiliaciones

Resumen

Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.© 2021. The Author(s).

Palabras clave